46.47MMarket Cap-1389P/E (TTM)
1.840High1.705Low304.80KVolume1.730Open1.720Pre Close534.80KTurnover1.26%Turnover RatioLossP/E (Static)25.54MShares5.33052wk High3.94P/B44.11MFloat Cap0.89052wk Low--Dividend TTM24.23MShs Float17.930Historical High--Div YieldTTM7.85%Amplitude0.890Historical Low1.754Avg Price1Lot Size
Gain Therapeutics Stock Forum
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure
shared via @Teddy123 Thanks!!
2 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease.
The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at a...
No comment yet